Highlights
Fenebrutinib demonstrated a 69% relative reduction in the total number of new T1 gadolinium-enhancing (Gd+) lesions compared to placebo (p=0.0022) at 12 weeks.
Data from the open-label extension (OLE) through week 48 showed a sustained annualized relapse rate (ARR) of 0.04, with 96% of participants remaining relapse-free.
